[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"opioid-use-disorder-oud\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:opioid-use-disorder-oud":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,54,78,109,138,165,190,227,254],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100599079","sparrow-link-neuromodulation-device-for-opioid-withdrawal-management-in-hospitalized-adults-with-opioid-use-disorder-100599079",false,"NCT07079826","Sparrow Link Neuromodulation Device for Opioid Withdrawal Management in Hospitalized Adults With Opioid Use Disorder","Sparrow Link Device for Opioid Withdrawal Management at UPMC Presbyterian With the Substance Treatment and Recovery Service (STARS; Formerly Addiction Medicine Consult Service)","Inclusion Criteria:\n\nEligible participants must meet at least ONE of the following criteria:\n\n1. Are continuing to experience opioid withdrawal symptoms:\n\n   1. Despite Maximal medical therapy with methadone, buprenorphine, full agonist opioids, or non-opioid medications,\n\n      or\n   2. During tapering or detox from full agonist opioids.\n\n   OR\n2. Have chosen to decline methadone or buprenorphine but still require support for withdrawal symptoms and\u002For pain management.\n\nAdditionally, participants must:\n\n* Be 18 years old or older.\n* Have active history of opioid use disorder.\n* Have a COWS score between 5-24 (Mild-moderate opioid withdrawal), indicating residual withdrawal symptoms.\n* Be able to provide informed consent.\n\nExclusion Criteria:\n\n* History of or active seizure disorder.\n* Presence of a cardiac device (e.g., pacemaker, defibrillator).\n* Presence of a neurostimulator (e.g., deep brain stimulator, spinal cord stimulator).\n* Pregnant or lactating individuals.\n* COWS score ≥ 25 (Severe Withdrawal), requiring medical stabilization.\n* Abnormal ear Anatomy, ear Infections, or skin Conditions at Electrode Sites, including congenital malformations, post-surgical changes, significant scarring, open wounds, or hypersensitivity.\n* Active neurological disorders, such as traumatic brain injury, stroke, multiple sclerosis, or other conditions that may interfere with neurostimulation effects or autonomic regulation as assessed at the investigator's discretion.\n* Severe alcohol or benzodiazepine withdrawal that is not adequately controlled with medication, per investigator discretion.\n* Known or documented allergy to hydrocolloid adhesives, as evidenced in the medical record.\n* Evidence of active psychosis, as documented in the medical record or reported by clinical staff.\n* Non-English speakers, whose limited English proficiency precludes informed consent or meaningful participation in study assessments validated only in English.","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study is evaluating the Sparrow Link, a wearable device that delivers gentle electrical signals to nerves in the outer ear (a technique known as transcutaneous auricular neurostimulation, or tAN). The goal is to assess whether the device is feasible to use, acceptable to patients, and may help reduce opioid withdrawal symptoms in hospitalized adults being treated for opioid use disorder (OUD). Participants will be randomly assigned to receive either the active device or a sham (inactive) version. Neither participants nor their clinical teams will know which version is used. All participants will continue receiving standard hospital care for opioid withdrawal. Researchers will collect information on how long participants use the device, whether they stop using it early, and changes in withdrawal severity. The study will also examine pain, craving, mood, anxiety, heart rate variability, and opioid use during hospitalization.",[26,27],"Opioid Withdrawal","Opioid Use Disorder (OUD)",[29,30,31,32,33,34,35,36,37,38,39,40,41],"transcutaneous auricular neurostimulation","Sparrow Link","tAN","vagus nerve stimulation","trigeminal nerve stimulation","neuromodulation","Clinical Opiate Withdrawal Scale","opioid craving","inpatient addiction care","withdrawal management","Addiction Medicine","anxiety","depression","RECRUITING","2026-05-27",{"date":45,"type":46},"2026-06-01","ACTUAL",{"date":43,"type":46},{"date":49,"type":20},"2027-12",{"name":51,"class":52},"Payel Roy","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":53},"100610360","mapping-ibogaine-neural-dynamics-in-opioid-use-disorder-100610360","NCT07226570","Mapping Ibogaine Neural Dynamics in Opioid Use Disorder","Central Neural Actions of Ibogaine in Opioid Use Disorder (OUD)","MIND-OUD","Inclusion Criteria:\n\n* Adults aged 21-70 with confirmed moderate to severe OUD as assessed by equal or greater than 4 symptoms using DSM-5 criteria.\n* Independently scheduled to receive ibogaine treatment at Ambio Life Sciences in Tijuana, Mexico.\n* Able to undergo MRI and EEG procedures at UC Irvine at Visit 1 (baseline), Visit 4, and Visit 5, totaling three sessions.\n* Able to complete psychometric surveys at each study time point.\n* Able to provide urine samples at all three scanning sessions at UCI.\n* Able to provide urine samples at a local external lab for 3- and 6-month follow-ups.\n* Capable of giving written informed consent.\n* Proficient ability to speak, read, and write in English.\n\nExclusion Criteria:\n\n* Presence of known past procedures, devices in the body, claustrophobia, or other contraindications for MRI.\n* Use of any psychedelic substances within 3 months prior to screening.\n* Diagnosis of schizophrenia, bipolar disorder (type I or II), or borderline personality disorder.\n* Use of ibogaine within 6 months prior to screening.\n* Pregnant or nursing. Participants who become pregnant during the study will be withdrawn from further participation.\n* Diagnosis of epilepsy or history of seizures.\n* Other contraindications to MRI\u002FEEG methods. These may include but are not limited to: brain surgical clips and surgical staples, metal implants in the brain, and certain metallic dental material.\n* Inability to complete MRI\u002FEEG sessions or follow-up visits.\n* Inability or unwillingness of an individual to give written informed consent.\n\nNote: UCI does not sponsor or financially support the ibogaine treatment in any way; all treatment costs are the sole responsibility of the participant.","21 Years","70 Years",{"count":65,"type":20},20,"OBSERVATIONAL","This study aims to understand how ibogaine treatment may change brain activity and symptoms in people with moderate-severe opioid use disorder (OUD), as defined by the DSM-5. Ibogaine is a plant-derived compound that some studies suggest can reduce opioid cravings and withdrawal. Participants in this study will already be independently scheduled to receive legal ibogaine treatment at a licensed clinic outside of the U.S. The University of California, Irvine (UCI) research team will not provide the treatment but will conduct brain imaging, administer psychometric questionnaires, and obtain urine samples throughout the course of this study. UCI does not sponsor or financially support the ibogaine treatment in any way; all treatment costs are the sole responsibility of the participant.\n\nThe main goal is to see if ibogaine changes brain function as assessed with magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), and electroencephalography (EEG). MRI\u002FMRS will measure brain activity when participants view opioid-related images, brain connectivity at rest, and levels of brain chemicals involved in craving and substance use. EEG will measure brain wave activity. MRI\u002FMRS\u002FEEG will be administered across 3 study time points. In addition, participants will complete psychometric surveys related to opioid craving, withdrawal symptoms, mood, anxiety, pain, and quality of life, along with urine tests to monitor substance use and screen for pregnancy.\n\nThe investigators hypothesize that after ibogaine treatment, participants will show reduced brain responses to opioid cues, changes in brain connectivity and chemistry, and improvements in self-reported cravings and other symptoms. This information may help researchers better understand how ibogaine works in the brain and whether it could play a role in future treatments for OUD.",[27],"2026-05-15",{"date":71,"type":46},"2026-05-18",{"date":73,"type":46},"2025-09-08",{"date":75,"type":20},"2027-05",{"name":77,"class":52},"University of California, Irvine",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":53},"100578256","phase-1-vk4-116-phase-i-study-with-food-effect-100578256","NCT06808932","VK4-116 Phase I Study With Food-Effect","A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study With Food-Effect Cohort to Assess the Safety, Tolerability, and Pharmacokinetics of Oral (R) VK4-116 in Healthy Volunteers","Inclusion Criteria:\n\n1. Be a healthy male or female volunteer between 18 and 60 years of age, inclusive, at the time of consent.\n\n   • The masculine \u002F feminine gender is used without any discrimination and with the aim to lighten the text.\n2. Have a body mass index (BMI) within a range of 17.0 to 36.0 kg\u002Fm2 and a minimum weight of at least 50.0 kg at screening.\n3. Be able to verbalize understanding of consent form, able to provide written informed consent, and verbalize willingness to complete study procedures.\n4. Have no clinically significant concurrent medical conditions determined by medical history, physical examination, clinical laboratory examination, vital signs, and 12-lead ECG.\n5. A female study participant must meet one of the following criteria:\n\n   * If of childbearing potential - agrees to use one of the accepted contraceptive regimens from at least 30 days prior to the first administration of the study medication, during the study, and for at least 30 days after the last dose of the study medication. An acceptable method of contraception includes one of the following:\n\n     i. abstinence from heterosexual intercourse, ii. hormonal contraceptives (e.g., injectable\u002Fimplant\u002Finsertable hormonal birth control products, transdermal patch), iii. intrauterine device (with or without hormones). OR agrees to use a double barrier method (e.g., condom and spermicide) during the study and for at least 30 days after the last dose of the study medication.\n   * If a female of non-childbearing potential - should be surgically sterile (i.e., has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation\u002Focclusion) or in a menopausal state (at least 1 year without menses), as confirmed by follicle stimulating hormone (FSH) levels (≥40 mIU\u002FmL).\n\n   A male study participant that engages in sexual activity must agree to use a double barrier method (e.g., condom and spermicide) and agree to not donate sperm during the study and for at least 90 days after the last dose of the study medication.\n6. Be able and willing to comply with protocol requirements and the rules and regulations of the study site, and be likely to complete all the study treatments.\n\nExclusion Criteria:\n\n1. Have any clinically significant finding within one year of Screening on medical history, physical examination, complete neurological examination, clinical laboratory test, vital signs or ECGs that contraindicate participation in the study. This includes, but is not limited to, history of or current cardiac, hepatic, renal, neurologic, gastrointestinal (GI), pulmonary, endocrinologic, hematologic, or immunologic disease or history of malignancy.\n2. Use nicotine products via smoking\u002Fvaping in past 6 months.\n3. Have a sitting systolic blood pressure (BP) \\>140 mmHg, diastolic BP \\>90 mmHg and heart rate (HR) \\\u003C45 or \\>100 beats per minute (BPM) at screening and clinic intake.\n4. History of unstable angina; a history of myocardial infarction; or a history of a clinically significant cardiac arrhythmia,\n5. Has a QT interval corrected for heart rate using Fredericia formula \\>450 milliseconds in males or \\>470 milliseconds in females, or evidence of left bundle branch blocks (Note: right bundle branch block is acceptable), second or third degree AV block, or evidence of left ventricular hypertrophy on ECG\n6. Have a history of liver disease or current elevation of aspartate aminotransferase (AST), alanine aminotransferase (ALT), 2 × the upper limit of normal (ULN).\n7. Have a history of renal disease or current renal function test values as follows:\n\n   * blood urea nitrogen (BUN) \\>2 × ULN,\n   * creatinine (Cr) \\>1.5 mg\u002FdL.\n8. Have donated blood (excluding plasma donation) of approximately 500 mL within 56 days prior to screening.\n9. Have donated plasma within 7 days prior to screening.\n10. Have hemoglobin value of \\\u003C13 g\u002FdL for men and \\\u003C12 g\u002FdL for women.\n11. Have undergone treatment with an investigational drug within 30 days or 5 times the half-life (whichever is longer) prior to screening.\n12. Have taken prescribed medications within 14 days of Day -1 or over-the-counter medications, dietary supplements, herbal products, or vitamins within 7 days or 5 half-lives (if known), whichever is longer, of Day -1.\n13. Have a positive urine drug test for alcohol, opioids (e.g., codeine, heroin, fentanyl, morphine, oxycodone, etc.), cocaine, amphetamine, methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA), benzodiazepines, tetrahydrocannabinol (THC), barbiturates, propoxyphene, or phencyclidine\u002Fphenylcyclohexyl piperidine (PCP) at admission.\n14. Have a history of suicide attempts or current or recent evidence of suicidal ideation in the past 12 months based on the Columbia-Suicide Severity Rating Scale (C-SSRS).\n15. Have a positive serology for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCVAb), or human immunodeficiency virus (HIV).\n16. Have positive results for a coronavirus disease 2019 (COVID-19) test.\n17. Have a history of anaphylaxis and known allergy to any drug formulation.\n18. Have a history of consumption of any product containing grapefruit, pomelo, Seville oranges, or alcohol within 7 days before study drug dosing on Day 1.\n19. Have consumed any product containing caffeine or xanthine within 24 hours before study drug dosing on Day 1",true,"60 Years",{"count":88,"type":20},48,[90],"PHASE1","This first-in-human, randomized, double-blind, placebo-controlled, single ascending dose (SAD), phase I study is designed to assess the safety, tolerability and pharmacokinetics of VK4-116 in healthy volunteers in fasted and fed state.",[93,27],"Opioid Dependence",[95,96,97],"addiction","dopamine","dopamine receptor","NOT_YET_RECRUITING","2026-04-06",{"date":101,"type":46},"2026-04-09",{"date":103,"type":20},"2026-08-01",{"date":105,"type":20},"2027-08-30",{"name":107,"class":108},"National Institute on Drug Abuse (NIDA)","NIH",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":21,"phases":119,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":53},"100619863","opioid-adherence-and-support-through-innovative-texting-strategies-100619863","NCT07350148","Opioid Adherence and Support Through Innovative Texting Strategies","Integrating Mindfulness and mHealth Approaches for Treating Opioid Use Disorder","OASIS","Inclusion Criteria:\n\n* 18 years of age or older\n* Have a cellphone that can receive text messages\n* Have internet access to complete study surveys\n* Willing to comply with all study procedures and be available for the duration of the study\n* Within 6 months of starting or resuming to take daily methadone or buprenorphine (or suboxone\u002Fsubutex)\n* Able to understand study requirements and provide informed consent\n\nExclusion Criteria:\n\n* None",{"count":118,"type":20},60,[23],"The goal of this clinical trial is to examine the effects of reminder and mindfulness text messages on medication adherence and managing craving, pain, and withdrawal symptoms in people taking medications for opioid use disorder through assessment questions collected twice daily during the course of treatment. The main questions it aims to answer are:\n\n1. Do daily medication reminder text messages increase medication adherence for people taking medications for opioid use disorder?\n2. To what extent do people engage with the daily mindfulness messages?\n3. What impact does daily mindfulness text message quantity have on craving, pain, forgetfulness, and withdrawal symptoms?\n\nParticipants will:\n\n1. Receive daily medication reminder text messages for at least 24 weeks (i.e., 6 months)\n2. Receive up to 6 mindfulness messages per day for 4 weeks (i.e., 1 month)\n3. Answer daily questions twice a day during the 4 weeks of mindfulness messages\n4. Answer questions about the study when enrolling, at the end of the 4 weeks of mindfulness messages, and at 4 and 16 weeks after the end of the mindfulness messages",[27,122],"Chronic Pain",[124,125,126,127,128],"text message","medications for opioid use disorder","mHealth","mindfulness","medication adherence","2026-01-15",{"date":131,"type":46},"2026-01-20",{"date":133,"type":46},"2025-10-13",{"date":135,"type":20},"2029-03",{"name":137,"class":52},"University of New Mexico",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":21,"phases":147,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":160,"leadSponsor":162,"locationsCount":164},"100599506","autonomous-methadone-delivery-system-by-nurses-100599506","NCT07085377","Autonomous Methadone Delivery System by Nurses","DIADEME","Inclusion Criteria:\n\n* Subject 18 years of age or older,\n* With opioid use disorder (OUD) according to DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) criteria (other authorized psychoactive substance use),\n* Intending to start methadone treatment for OUD in a CSAPA center within 7 days,\n* Agreeing to be followed up in a CSAPA over the next 3 months,\n\nExclusion Criteria:\n\n* Having taken methadone treatment (on prescription) in the three months prior to inclusion,\n* Simultaneous medical care in another addictology facility,\n* with a day-hospital project,\n* Referral to town prescriber or town pharmacy planned and\u002For requested by patient before 3 month,\n* Non-stabilized psychiatric disorder or cognitive impairment likely to compromise compliance and involvement in care (at investigator's discretion),\n* Inability to communicate and express themselves in French language,\n* Subject to a legal protection measure other than curatorship,\n* Pregnant or breast-feeding.",{"count":146,"type":20},182,[23],"Initiations of methadone treatment for opiode use disorder (OUD) are carried out in France in specialized centers, known as centers for care, support and prevention in addictology (CSAPA) In this way, hospital practitioners initiate the prescription of methadone, which is delivered on the spot by the nursing team. CSAPA nurses, and addictology nurses more generally, have a real range of skills which can include adapting treatment doses according to a protocol pre-established in a team, and medically validated (French law no. 2019-774 of July 24, 2019 relating to the organization and transformation of the healthcare system).\n\nThe methadone speciality used for initiation in CSAPAs is almost always the syrup form. The capsule form can only be used after one year's treatment, unless exceptionally authorized by the medical officer of the French National Health Insurance Fund. However, regulations stipulate that the prescription of methadone syrup must be renewed every fourteen days, which in theory means that a CSAPA doctor must see the patient at least twice a month to renew the prescription, throughout the entire course of treatment.\n\nIn practice, medical resources are often not sufficient for patients to be seen by a doctor at such a rate. Numerous palliative organizations exist, though they remain poorly described and documented. In some centers, doctors focus primarily on initiations, and prescriptions for patients for whom \"stability\" has been achieved are sometimes renewed for longer periods than fourteen days, with nurses in charge of assessing whether this organization is suitable for the patient. The notion of stability varies significantly from one center to another, and may mean achieving a constant dose, stopping illicit opioid use, or other criteria more focused on the patient's psychosocial reintegration. By outlining the missions of Addictology nurses, and more specifically of CSAPA nurses, the investigators can define the essential skills required of nurses to carry out these missions.\n\nThe main hypothesis of the DIADEME study is that semi-autonomous management of methadone treatment initiation by CSAPA nursing teams helps to reinforce adherence to care and thus improve retention rates in the 3 months following initiation.",[27,150],"Addictology",[152,153,154,155],"Opioid use disorder (OUD)","Methadone","Autonomous nursing system medication delivery","Nursing Care Delivery System","2025-12-08",{"date":158,"type":46},"2025-12-16",{"date":156,"type":46},{"date":161,"type":20},"2028-04-08",{"name":163,"class":52},"Hospices Civils de Lyon",8,{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":21,"phases":176,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100588382","phase-3-adjunctive-cannabidiol-for-recovery-from-opioid-study-100588382","NCT06940674","Adjunctive Cannabidiol for Recovery From Opioid Study","Adjunctive Cannabidiol for Recovery From Opioid Study (ACROS)","ACROS","Inclusion Criteria:\n\n* Individuals between 18 and 65 years old.\n* Ability to understand and give informed consent.\n* Current opioid use disorder (OUD) or OUD in remission while on maintenance therapy with OAT, as determined by DSM-5 with the M.I.N.I. interview (Mini-International Neuropsychiatric Interview).\n* Current opioid agonist maintenance treatment with methadone or buprenorphine for at least 14 days prior to consent. With the following more specific criteria for each of these two medications:\n\n  * Current methadone maintenance treatment with a dose of ≥ 10mg\u002Fday, (maximum: 250mg\u002Fday), AND urinary toxicology positive for methadone and 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP).\n  * Current buprenorphine maintenance treatment with a dose of ≥ 2mg\u002Fday (maximum: 32mg\u002Fday), AND urinary toxicology positive for buprenorphine.\n\nExclusion Criteria:\n\n* Participants who are non-English speaking.\n* Psychiatric conditions under DSM-5 (examined with the MINI) that would make study participation unsafe, or which would prevent adherence to study procedure; examples include: suicidal (i.e. high risk for suicide on the Columbia suicide severity rating scale (C-SSRS) screen version) or homicidal ideation requiring immediate attention, inadequately-treated mental health disorder (e.g., active psychosis, uncontrolled bipolar disorder).\n* Current diagnosis of a severe substance use disorder (except for opioid and nicotine\u002Ftobacco) in the past 3 months, based on the MINI interview, that would preclude safe participation in the study as determined by the study medical clinician.\n* Signs of acute drug intoxication when arriving at the study site as determined by clinician assessment.\n* Medical or psychiatric contraindications for CBD administration (e.g., history of hypersensitivity to cannabinoids); or any of the ingredients in the product (gelatin or sesame oil).\n* Showing signs of acute opioid withdrawal symptoms (as determined by the result of the Clinical Opiate Withdrawal Scale (COWS). A Score of ≥ 5 or as interpreted by the investigator will be considered a positive result for withdrawal symptoms).\n* Have a medical condition that would make study participation unsafe, which would make treatment compliance difficult, or would prevent adherence to study procedure. This includes but is not limited to the following criteria: • \\\u003C 30mL\u002Fmin\u002F1.73m2 eGFR. •QTc Fridericia \\> 500ms at screening. •Elevated liver enzymes at screening. The exclusionary lab values are: \\>4x the upper limit of normal (ULN) per laboratory criteria for AST or ALT or \\>1.5x ULN for bilirubin.\n* Participating in another pharmacotherapeutic trial in the past 3 months.\n* Participants who have used (within 14 days prior to consent) or plan to use (during the 24-week treatment period) any medications, dietary supplements (and\u002For grapefruit juice), or combination of medications and supplements known to alter the metabolism of, or interact with CBD (buproprion, rifampin, barbiturates, phenothiazines, cimetidine, anticoagulants, antiplatelets, etc.).\n* For women: being pregnant (positive urine test for pregnancy) or breastfeeding.\n* Not using an appropriate method of contraception such as hormonal contraception (oral hormonal contraceptives, Depo-Provera, Nuva-Ring), intrauterine device (IUD), sterilization, or double barrier method (combination of any two barrier methods used simultaneously, i.e. condom, spermicide, diaphragm).\n* Participants who have been court mandated to attend treatment centers","65 Years",{"count":175,"type":20},450,[177],"PHASE3","The long-term goal of the project is to determine whether cannabidiol (CBD) can reduce craving and relapse in individuals with opioid use disorder (OUD). The first phase of this project was an open cross-over design study in healthy individuals to confirm the safety and pharmacokinetic (PK) effects of CBD (BSPG CBD; Brains Bioceutical). The second phase was a double-blinded randomized controlled trial to determine whether CBD reduces craving and anxiety in individuals with OUD maintained on opioid agonist therapy. This phase 3 trial will determine whether CBD can serve as a potential adjunct treatment to reduce illicit opioid use in individuals with OUD maintained on opioid agonist therapy.",[27],"2025-12-04",{"date":182,"type":46},"2025-12-11",{"date":184,"type":46},"2025-06-13",{"date":186,"type":20},"2027-08-15",{"name":188,"class":52},"Icahn School of Medicine at Mount Sinai",2,{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":197,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":21,"phases":201,"briefSummary":202,"conditions":203,"keywords":205,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":53},"100609429","individualized-adaptive-deep-brain-stimulation-in-opioid-use-disorder-100609429","NCT07214467","Individualized Adaptive Deep Brain Stimulation in Opioid Use Disorder","aDBS OUD","Inclusion Criteria:\n\n* Adults (all genders) 22 to 75 years old.\n* Current diagnosis of severe primary opioid use disorder (OUD) (\\>= 6 on DSM-5 OUD criteria) (any form of opioid use).\n* History of opioid use for more than 5 years.\n* Participants are seeking treatment for their OUD.\n* Participants have insight into their opioid use disorder (score \\> 26 on the recognition subscale of the Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES V.8))\n* OUD is treatment refractory: unable to achieve sustained remission over the past 5 years, despite at least three treatment attempts (outpatient, residential, inpatient), with at least one treatment attempt involving taking a first-line medication for OUD (MOUD) such as buprenorphine, methadone, or extended-release naltrexone. Treatment failure is defined as continued opioid use or relapse during or after completion of treatment. Sustained remission is defined per DSM-5 as not meeting any OUD criteria except craving for \\> 12 months. Documented adherence: participants must have documented adherence to the failed first-line MOUD for at least 8 weeks (PMID: 29083570).\n* Stated willingness to comply with all study procedures and availability for the duration of the study.\n* Social support system and stable living arrangement to provide assurances that the subject will adhere to study requirements: family or friends who live with or near the subject, and can provide collateral information, monitor the subject's behavior, support, and encourage the subject to participate in follow-up visits and evaluations.\n* For individuals of reproductive potential: use of highly effective contraception for at least 4 weeks prior to sEEG surgery and agreement to use such a method during study participation.\n\nExclusion Criteria:\n\n* Pregnancy or lactation.\n* Non-English speaking.\n* Participants are not willing to start MOUD treatment with buprenorphine or to switch MOUD to buprenorphine if they are already on other MOUD, for the duration of the study.\n* OUD treatment with another investigational drug or other intervention within 3 months.\n* History of primary psychosis or Bipolar I disorder per the medical interview.\n* History of severe personality disorder that could interfere with study participation (e.g., antisocial personality disorder) per the medical interview.\n* History of traumatic brain injury with loss of consciousness greater than 5 minutes.\n* Clinically significant cognitive impairment per neuropsychological testing.\n* History of suicidal attempts in the past 3 years or current suicidal thoughts per psychiatric evaluation.\n* Coagulopathy: INR \\> 1.4, aPTT \\> 40 s, platelets \\\u003C 100,000.\n* Current clinically significant medical or neurologic disease that affects brain function (e.g., recent stroke, myocardial infarction, seizures not due to alcohol withdrawal).\n* Clinically significant abnormality on structural brain MRI scan.\n* Life expectancy less than 24 months per the clinical judgment of study investigators (e.g., terminal cancers).\n* Any labeled DBS contraindication or inability to have brain MRI: certain pacemakers, metal in body, inability to undergo awake operation, significant cardiac or other medical risk factors for surgery, infection, and coagulopathy.\n* Exclusion for early remission: participants who achieve early remission after initiating buprenorphine during the screening phase (prior to the sEEG phase) will be excluded from the study.","22 Years","75 Years",{"count":200,"type":20},6,[23],"The purpose of this study is to determine if personalized (adaptive) Deep Brain Stimulation (DBS) based upon invasive brain mapping is safe and can lead to better outcomes like reductions in craving and opioid use.",[204,27],"Substance Use Disorder (SUD)",[206,207,208,209,210,211,212,213,214,215,216,217],"Opioid","SUD","OUD","Substance Use","Substance Use Disorder","Addiction","Opioid Use Disorder","Opioid Use","deep brain stimulation","Neuromodulation","stereo-EEG","brain mapping","2025-10-25",{"date":220,"type":46},"2025-10-28",{"date":222,"type":46},"2025-10-24",{"date":224,"type":20},"2031-11-22",{"name":226,"class":52},"University of California, San Francisco",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":21,"phases":236,"briefSummary":237,"conditions":238,"keywords":239,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":53},"100583556","phase-1-methaload-dose-finding-study-100583556","NCT06877858","MethaLoad Dose-Finding Study","A Dose-Finding Study of Methadone Loading Dose Initiation for Opioid Use Disorder With Fentanyl Use","Inclusion criteria:\n\n1. Male, female, transgender, or non-binary, aged 18 years or older\n2. DSM-5 criteria for opioid use disorder, moderate-severe\n3. Fentanyl positive urine drug test\n4. Able to provide a dated \\& written informed consent in English prior to the conduct of any study related procedures\n5. Stated willingness to comply with all study procedures and availability for the duration of the study\n6. Ability to take oral medication and be willing to adhere to the dosage regimen\n7. Interest in starting methadone treatment for opioid use disorder at one of three locations: Merakey Parkside at 5000 Parkside, Merakey 5429 Germantown Avenue, or Merakey 1745 North 4th Street\n8. Reliable access to a working phone\n\nExclusion criteria:\n\n1. Hypersensitivity or allergy to methadone that is previously documented\n2. Pregnancy or actively lactating (with urine pregnancy test performed on screening and repeated on admission to the unit prior to randomization)\n3. Taking medications for opioid use disorder, per self-report or per urine drug testing detection of buprenorphine or methadone\n4. At risk of benzodiazepine or alcohol withdrawal as defined by: prior benzodiazepine or alcohol withdrawal in the past 3 months, current daily use of benzodiazepines or alcohol, or DSM-5 criteria for hypnotic-sedative or alcohol use disorder\n5. At risk of severe medetomidine withdrawal based on: serum or urine testing for medetomidine (if available), prior withdrawal syndrome requiring intensive care unit admission within past 6 months, and\u002For severe nausea\u002Fvomiting during first 4 hours of withdrawal, at the discretion of the study physicians\n6. At risk for methadone-induced QT-prolongation: prolonged QTc on screening or admission EKG (greater than 450ms in men, greater than 460ms in women), history of QT prolongation, previously documented long QT syndrome, history of ventricular arrhythmia (e.g., torsades de pointes), history of cardiac hypertrophy, history of cardiac conduction abnormalities, taking medications that affect cardiac conduction (at study physician discretion; including but not limited to: amiodarone, flecainide, sotalol, azithromycin, ciprofloxacin, levofloxacin, citalopram, escitalopram, hydroxychloroquine, chlorpromazine, haloperidol, donepezil, ibogaine, cilostazol), serum potassium concentration less than 3.5 mg\u002FdL, or serum magnesium concentration less than 1.7 mg\u002FdL.\n7. Significant hepatic dysfunction, defined as: AST and\u002For ALT 3x upper limit of normal, or total bilirubin 1.5x upper limit of normal\n8. Significant renal dysfunction, defined as: eGFR less than or equal to 60 mL\u002Fmin\n9. Chronic hypotension (\\\u003C90\u002F50 mmHg) or episodic symptomatic hypotension, defined as a history of active or recurrent orthostatic hypotension or syncope\n10. Significant pulmonary disease, defined as: baseline SpO2 \\\u003C95% on screening or admission, requiring oxygen at home (chronically or at bedtime), or COPD with modified MRC Dyspnea Scale greater than 2 (\"I stop for breath after walking about one city block\")\n11. Suspected gastrointestinal obstruction, per medical history\n12. Active, chronic use of the CYP3A4-inducers or -inhibitors rifampin, phenytoin, St John's wort, phenobarbital, carbamazepine, voriconazole, efavirenz, nelfinavir, nevirapine, ritonavir, and lopinavir\u002Fritonavir, abacavir, or amprenavir\n13. Pending legal action that could prohibit participation and\u002For compliance in study procedures\n14. Presence of any other psychiatric and\u002For medical disorder that, in the opinion of the PI, will interfere with completion of the study or place the patient at heightened risk through participation in the study.",{"count":235,"type":20},24,[90],"The goal of this study is to develop a loading dose approach to starting methadone to treat opioid use disorder with fentanyl use (\"fentanyl OUD\", herein). This study is a participant- and assessor- blinded dose-finding study using the Bayesian optimal interval (BOIN) design. Investigators aim to recruit n=24 participants with fentanyl OUD to a research unit for monitored methadone initiation. Participants will be randomized to standard initiation vs. loading dose initiation at one of four doses.",[27],[240,241,242,243,244,208],"methadone","fentanyl","opioid use disorder","opioid addiction","opiate addiction","2025-10-09",{"date":247,"type":46},"2025-10-14",{"date":249,"type":46},"2025-09-25",{"date":251,"type":20},"2027-07",{"name":253,"class":52},"University of Pennsylvania",{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":261,"minAge":17,"maxAge":198,"enrollmentInfo":262,"targetDuration":4,"studyType":21,"phases":264,"briefSummary":265,"conditions":266,"keywords":267,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":4},"100608954","contingency-management-for-opioid-use-disorder-in-inpatients-at-assiut-university-hospital-100608954","NCT07208266","Contingency Management for Opioid Use Disorder in Inpatients at Assiut University Hospital","Contingency Management as a Behavioral Intervention for Patients With Opioid Use Disorder : Implementation and Efficacy in the Inpatient Setting at Assiut University Hospital.","Inclusion Criteria:\n\n* Be 18 years of age or older\n* Have a diagnosis of a substance use disorder (SUD) according to DSM-5 criteria\n* Be able to understand and provide informed consent\n* Be willing to comply with study procedures, including regular drug screening and attendance tracking\n* Must be able to swallow tablets\n\nExclusion Criteria:\n\n* Have a severe cognitive impairment or active psychosis that interferes with participation\n* Currently experiencing a medical condition that would make participation unsafe","MALE",{"count":263,"type":20},55,[23],"A scientific study to design and implement a contingency management (CM) program, and to evaluate its effectiveness in promoting abstinence and treatment adherence among individuals with opioid use disorder, as well as to explore its potential for broader implementation in clinical settings.",[27],[212,268,269],"Contingency Management","Assiut University Hospital","2025-09-27",{"date":272,"type":46},"2025-10-06",{"date":274,"type":20},"2025-12-01",{"date":276,"type":20},"2027-02-01",{"name":278,"class":52},"Assiut University"]